• Blood Cancer Research Partnership

    Clinical Trials

    Open to Enrollment

    CTEP: 9204/DFCI 12-537: A Phase I/Ib Study of Ipilimumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation 

    Participating Sites:

    • Blood and Marrow Transplant Group of Georgia at Northside Hospital 
    • Maine Center for Cancer Medicine 
    • Colorado Blood Cancer Institute 

    TH-CR-408/DFCI 11-425: A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma 

    Participating Sites:

    • Florida Cancer Affiliates/Ocala Oncology 
    • Maine Center for Cancer Medicine 
    • New York Oncology Hematology 
    • Pacific Cancer Care 
    • West Cancer Center 

    NCT# 01822509 to CTEP: 9204/DFCI 12-537 

    NCT # 01522872 to TH-CR-408/DFCI 11-425 

    A Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients with Hematologic Malignancies (NCT# 01416428) 

    Participating Sites:

    • Colorado Blood Cancer Institute  
    • Columbia Basin Hematology Oncology 
    • Hematology-Oncology Associates of Northern New Jersey  
    • New York Oncology Hematology 
    • Pacific Cancer Care 
    • Virginia Piper Cancer Institute  

    Enrolling Soon/In-Development

    • A Multicenter Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies
    • A Prospective, Longitudinal, Observational Study in Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome
    • A Phase II study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma
    • A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia 
    • Phase II Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma 

     

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms